Immunovant Inc (IMVT) Stock Price, Quote & News

Company Profile

Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren's disease; and batoclimab for myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and thyroid eye disease. The company was founded in 2018 and is based in New York, New...

Industry: Biotechnology

Sector: Healthcare

Phone: 917 580 3099

Website: immunovant.com

Address:

320 West 37th Street, 6th Floor, New York, United States

TradeTracs Feb. 24 at 10:14 PM

$IMVT solid horizontal base continuation through last earnings. 27.50-28 trigger

0 · Reply

StockConsultant Feb. 24 at 2:22 PM

$IMVT Immunovant stock, watch for a top of range breakout, mulitple attempts at https://stockconsultant.com/?IMVT

0 · Reply

UgoGreg Feb. 21 at 4:05 PM

$IMVT https://youtu.be/ygBN8MilTyc

0 · Reply

OfficialStocktwitsUser Feb. 21 at 10:59 AM

$IMVT RSI: 53.36, MACD: 0.1493 Vol: 0.73, MA20: 26.17, MA50: 26.06 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

TheCentWise Feb. 19 at 8:39 AM

$IMVT Immunova to Acquire AlphaTON Subsidiary Iox Therapeutics Immunova has moved to acquire AlphaTON's cancer-treatment subsidiary, Iox Therapeutics, in a deal that signals a strategic pivot for a crypto-focused treasury firm as markets swing in 2026. https://thecentwise.com/cryptocurrency/immunova-to-acquire-alphaton-subsidiary-iox-therapeutics

0 · Reply

Quantumup Feb. 18 at 1:28 PM

Truist reiterated $VRDN Buy-$40 and said, REVEAL-1 Topline Preview: Ele' Positioned to Hit Proptosis Bar, after its KOLs check. $AMGN $IMVT - ROIV NVS $ALMS $TRML Truist additionally said, Ahead of VRDN's REVEAL-1 topline for elegrobart (Ele', fka VRDN-003 SC), a half-life extended, SC, IGF-1Ra for active TED, we checked in with KOLs for updated views on Ele' and the broader story. While management targets a 50-70% placebo-adjusted proptosis responder rate, physicians would accept the low end given the strong convenience advantage. Ele' is seen as a potential "game-changer" particularly in chronic and low-CAS patients. A REVEAL-1 win would meaningfully de-risk REVEAL-2 in 2Q and support our ~ $1.3B peak revenue est. Our check-in on volatility surface and the options book for VRDN aligns with our positive views, NT and LT. Reiterate Buy, $40 PT.

0 · Reply

SuperGreenToday Feb. 11 at 2:12 PM

$IMVT Share Price: $26.68 Contract Selected: May 15, 2026 $25 Calls Buy Zone: $3.21 – $3.97 Target Zone: $5.84 – $7.14 Potential Upside: 72% ROI Time to Expiration: 92 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Alfalcon Feb. 9 at 11:23 PM

$ROIV our dove finally outpaced $IMVT

0 · Reply

ZacksResearch Feb. 9 at 6:48 PM

$IMVT just surprised the Street — and the pipeline is front and center 👀 Immunovant posted a narrower-than-expected Q3 loss, raised $550M to fund IMVT-1402 through launch, and is advancing multiple studies with key data ahead — plenty for investors to digest. Full pipeline and funding breakdown here 👉 https://www.zacks.com/stock/news/2841900/imvt-posts-narrower-than-expected-q3-loss-pipeline-in-focus?cid=sm-stocktwits-2-2841900-teaser-32666&ADID=SYND_STOCKTWITS_TWEET_2_2841900_TEASER_32666

0 · Reply

ZacksResearch Feb. 9 at 5:48 PM

$IMVT narrows Q3 loss but no revenue yet — what’s driving the stock? 🤔 📈 Shares surged 38.6% over the past year, beating the industry’s 20.3% growth. 🤑 Raised $550M in December 2025 to fund IMVT-1402’s potential commercial launch. Discover the full story behind IMVT’s pipeline and financials here 👉 https://www.zacks.com/stock/news/2841900/imvt-posts-narrower-than-expected-q3-loss-pipeline-in-focus?cid=sm-stocktwits-2-2841900-body-32665&ADID=SYND_STOCKTWITS_TWEET_2_2841900_BODY_32665

0 · Reply

Immunovant, Inc. (IMVT) Q3 2026 Earnings Call Transcript

Feb 6, 2026, 7:00 AM EST - 20 days ago

Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025

Jan 23, 2026, 5:25 PM EST - 4 weeks ago

Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026

Dec 12, 2025, 4:28 PM EST - 2 months ago

Immunovant: 'Buy' On Competitive Batoclimab Landscape And IMVT-1402 Advancement

Dec 11, 2025, 1:29 AM EST - 2 months ago

Immunovant Announces Pricing of $550 Million Common Stock Financing

Nov 10, 2025, 12:31 PM EST - 3 months ago

Immunovant, Inc. (IMVT) Q2 2026 Earnings Call Transcript

Nov 10, 2025, 7:00 AM EST - 3 months ago

Immunovant Provides Corporate Updates and Reports Financial Results for the Second Quarter Ended September 30, 2025

Oct 27, 2025, 4:10 PM EDT - 4 months ago

Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025

ROIV

Sep 3, 2025, 12:57 PM EDT - 6 months ago

Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients

Aug 27, 2025, 8:33 PM EDT - 6 months ago

IMVT Investors Have Opportunity to Join Immunovant, Inc. Fraud Investigation with the Schall Law Firm

Aug 11, 2025, 7:00 AM EDT - 7 months ago

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2025

May 29, 2025, 7:00 AM EDT - 9 months ago

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025

Mar 19, 2025, 5:07 PM EDT - 1 year ago

Immunovant: TED Data Sets Stage For Batoclimab Regulatory Filings Going Forward

Mar 19, 2025, 7:59 AM EDT - 1 year ago

Immunovant's muscle disorder treatment meets main goal in late-stage trial

Mar 19, 2025, 7:45 AM EDT - 1 year ago

Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies

Mar 18, 2025, 4:32 PM EDT - 1 year ago

Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs

Feb 6, 2025, 6:30 AM EST - 1 year ago

Immunovant Reports Financial Results for the Quarter Ended December 31, 2024

Jan 24, 2025, 1:34 PM EST - 1 year ago

Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm

Dec 27, 2024, 10:50 AM EST - 1 year ago

Immunovant: Continued FcRn Targeting With IMVT-1402 Pivotal Study

Dec 11, 2024, 6:25 AM EST - 1 year ago

FcRn Inhibitor Market Size, Target Population, Competitive Landscape & Forecast to 2034 - Immunovant Advances FcRn Inhibitor Pipeline with Promising Results and FDA Green Light for Pivotal Trial

Nov 7, 2024, 6:30 AM EST - 1 year ago

Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024

Oct 29, 2024, 6:30 AM EDT - 1 year ago

Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves' Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting

Sep 9, 2024, 9:12 AM EDT - 1 year ago

Top 2 Health Care Stocks That May Collapse This Quarter

TERN

Sep 9, 2024, 3:55 AM EDT - 1 year ago

Immunovant Provides Update on Graves' Disease Development Program

Sep 5, 2024, 6:30 AM EDT - 1 year ago

Immunovant to Host Graves' Disease Program Update on September 9, 2024

Aug 6, 2024, 8:25 AM EDT - 1 year ago

Long Assets On Path To Creating Significant Value, Shorting Remains Very Challenging

FIP FTAI OABI PRPL REAL RICK

May 29, 2024, 4:01 PM EDT - 1 year ago

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024

Apr 4, 2024, 2:12 AM EDT - 2 years ago

Immunovant: Strategic Edge In The Autoimmune Sector (Rating Upgrade)

Mar 12, 2024, 7:30 AM EDT - 2 years ago

Immunovant Awarded U.S. Patent for IMVT-1402

Feb 12, 2024, 7:00 AM EST - 2 years ago

Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended December 31, 2023

Jan 9, 2024, 9:00 AM EST - 2 years ago

Chris DeMuth Sure Likes Uranium And SHF Holdings + 3 Litigation Ideas

BUR LQDA

Jan 3, 2024, 8:00 AM EST - 2 years ago

Immunovant to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 20, 2023, 4:30 PM EST - 2 years ago

Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves' Disease

Dec 14, 2023, 1:24 PM EST - 2 years ago

Best Small-Cap Stocks to Buy for 2024 and Beyond

ARVN ASO BOOT FLYW GH PRVA RCKT

Nov 28, 2023, 7:00 AM EST - 2 years ago

Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential

Nov 14, 2023, 3:48 AM EST - 2 years ago

Immunovant: Q3 Earnings, Navigating Risks And Rewards In The Autoimmune Arena

Nov 13, 2023, 8:00 AM EST - 2 years ago

Immunovant to Present at Upcoming Investor Conferences

Nov 9, 2023, 7:00 AM EST - 2 years ago

Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended September 30, 2023

Oct 2, 2023, 4:52 PM EDT - 2 years ago

Immunovant Announces Closing of Upsized Common Stock Financing and Full Exercise of Underwriters' Option to Purchase Additional Shares

Sep 27, 2023, 11:41 PM EDT - 2 years ago

Immunovant Announces Pricing of $450 Million Common Stock Financing

Sep 27, 2023, 5:30 AM EDT - 2 years ago

Immunovant: Immune Boost, From Clinical Trials To An Aggressive Bullish Stock

Sep 26, 2023, 5:00 PM EDT - 2 years ago

Immunovant Announces Proposed Offering of $300 Million of Common Stock

Sep 26, 2023, 4:20 PM EDT - 2 years ago

Immunovant Shares Skyrocket After Trial of Its Autoimmune Drug Beats Expectations

Sep 26, 2023, 11:10 AM EDT - 2 years ago

Immunovant: Data Sizzles, But The Steak Isn't Done Yet (Rating Upgrade)

Sep 26, 2023, 7:57 AM EDT - 2 years ago

Immunovant shares surge after antibody treatment succeeds in early-stage study

Sep 26, 2023, 6:00 AM EDT - 2 years ago

Immunovant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results

Sep 25, 2023, 11:01 PM EDT - 2 years ago

Immunovant to Host Conference Call and Webcast to Report Initial IMVT-1402 Phase 1 Results on September 26, 2023

TradeTracs Feb. 24 at 10:14 PM

$IMVT solid horizontal base continuation through last earnings. 27.50-28 trigger

0 · Reply

StockConsultant Feb. 24 at 2:22 PM

$IMVT Immunovant stock, watch for a top of range breakout, mulitple attempts at https://stockconsultant.com/?IMVT

0 · Reply

UgoGreg Feb. 21 at 4:05 PM

$IMVT https://youtu.be/ygBN8MilTyc

0 · Reply

OfficialStocktwitsUser Feb. 21 at 10:59 AM

0 · Reply

TheCentWise Feb. 19 at 8:39 AM

0 · Reply

Quantumup Feb. 18 at 1:28 PM

0 · Reply

SuperGreenToday Feb. 11 at 2:12 PM

0 · Reply

Alfalcon Feb. 9 at 11:23 PM

$ROIV our dove finally outpaced $IMVT

0 · Reply

ZacksResearch Feb. 9 at 6:48 PM

0 · Reply

ZacksResearch Feb. 9 at 5:48 PM

0 · Reply

ortega1963 Feb. 9 at 9:03 AM

$IMVT Spread your Wings and fly away

0 · Reply

NasdaqKnight Feb. 7 at 3:33 PM

🚨 $IMVT Update | PT $50 Lifesciences company stays laser-focused on execution across multiple late-stage programs. Key catalysts coming in 2026: If this is helpful to you, tap @NasdaqKnight • TED data expected H1 2026 • RA & CLE data expected H2 2026 Investors should watch these readouts—they could be major drivers for $IMVT shares as the pipeline progresses. Multiple late-stage shots on goal make 2026 a potentially high-action year.

0 · Reply

d_risk Feb. 6 at 6:37 PM

$IMVT - Immunovant Inc. Common Stock - 10Q - Updated Risk Factors IMVT flags rising R&D and trial cost/timing risk, tighter exposure to material breaches in key licensing that could trigger damages or loss of IP rights, and new uncertainty around whether its cross-border tax structure will deliver intended benefits. #Biotechnology #TaxUncertainty #IntellectualProperty #LicensingRisk #R&DRisk 🟢 Added 🟠 Removed https://d-risk.ai/IMVT/10-Q/2026-02-06

0 · Reply

TrendEdgeLogan Feb. 6 at 4:26 PM

$IMVT the table is set

0 · Reply

StocktwitsEarnings Feb. 6 at 2:03 PM

$IMVT Q3 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.61 up 19.74% YoY • Immunovant expects its $994.5 million cash and cash equivalents as of December 31, 2025, to fund operating expenses and capital requirements for announced indications through the potential commercial launch of IMVT-1402 in GD.

0 · Reply

theoptionsplug Feb. 6 at 4:00 AM

THINGS TO WATCH, FRIDAY, 2/6/26 👁️ $TM $CNC $IMVT $MSTR $COIN

0 · Reply

G101SPM Feb. 5 at 8:13 PM

#SHOWTIME Immunovant Inc Business Update Call (February 6) Scheduled to appear: $IMVT Amentum Holdings Inc Annual General Meeting (February 6) Scheduled to appear: $AMTM

0 · Reply

OfficialStocktwitsUser Feb. 5 at 12:35 PM

$IMVT RSI: 30.50, MACD: 0.0956 Vol: 0.45, MA20: 26.20, MA50: 25.37 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

SuperGreenToday Feb. 2 at 2:58 PM

$IMVT Share Price: $26.00 Contract Selected: May 15, 2026 $25 Calls Buy Zone: $3.21 – $3.97 Target Zone: $5.15 – $6.30 Potential Upside: 51% ROI Time to Expiration: 101 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

SuperGreenToday Jan. 30 at 2:35 PM

$IMVT Share Price: $26.19 Contract Selected: May 15, 2026 $25 Calls Buy Zone: $3.21 – $3.97 Target Zone: $5.62 – $6.87 Potential Upside: 65% ROI Time to Expiration: 104 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Quantumup Jan. 28 at 1:28 PM

Evercore ISI⬆️ $VRDN's PT to $45 from $44 and reiterated at an Outperform rating. $AMGN $IMVT - $ROIV $NVS TEVA Here's what Evercore ISI said in its note: https://x.com/Quantumup1/status/2016502597268471892?s=20

0 · Reply

parcha Jan. 25 at 11:28 PM

$IMVT DURHAM, N.C. and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the third quarter ended December 31, 2025, and provide a business update at 8:00 a.m. ET on Friday, February 6, 2026. https://finance.yahoo.com/news/immunovant-report-financial-results-third-222500688.html

0 · Reply

Market Cap	5.57B
Revenue (ttm)	0.00
Net Income (ttm)	-413.84M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,884,100
Avg Vol	1,604,602
Day's Range	N/A - N/A
Shares Out	203.53M
Stochastic %K	51%
Beta	0.54
Analysts	Strong Sell
Price Target	$40.62